Protein C

Octapharma's Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Retrieved on: 
Wednesday, July 26, 2023
Embolism, Factor IX, Bleeding, Health, Prothrombin time, Factor X, Stroke, Food and Drug Administration, Clinical trial, Thrombophilia, VKA, Octapharma, PCC, INR, Coagulation, Warfarin, Hemostasis, Patient, Protein C, Risk, Physician, Coagulation factor VII, Vitamin K, Trial of the century, Phase, FDA, Thrombin, Food, Safety, Pharmaceutical industry, Medical imaging

Balfaxar® helps restore blood coagulation by replenishing the levels of clotting factors that are deficient due to warfarin therapy.

Key Points: 
  • Balfaxar® helps restore blood coagulation by replenishing the levels of clotting factors that are deficient due to warfarin therapy.
  • The Phase III, randomized, double-blind, multicenter study was performed at 24 sites in the U.S. and Europe and randomized 208 patients to Balfaxar® (N=105) or control 4F-PCC (N=103).
  • We are confident Balfaxar® will be a welcomed treatment for physicians who need to quickly restore patients' coagulation."
  • Balfaxar®, a lyophilized powder for reconstitution, will be provided with sterile water for injection and the new transfer device, nextaro ®.

2022 U.S. Coagulation Testing Market Report: Identify and Evaluate Emerging Business Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Research, Managed Care, General Health, Medical Devices, Hospitals, Health Technology, Clinical Trials, Science, Surgery, Biotechnology, Other Science, Health, ACT, Factor VII, Factor XII, Factor, Factor XI, Factor IX, APTT, Protein S, Activated protein C resistance, Thrombin time, Antithrombin, Bleeding time, Protein C, Factor X, Prothrombin time, Consumables, Factor V, Factor VIII, Prekallikrein, Comparison, Factor XIII, Fibrinogen, Marketing, Retail, Vaccine, Fine chemical, Pharmaceutical industry, Plasmin

The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities in the US coagulation testing market during the next five years.
  • The report is available by section, and can be customized to specific information needs and budget.
  • The report explores business and technological trends in the US coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

Now available from Aniara Diagnostica: LIAPHEN™ Protein C, Immuno-turbidimetric method for the in vitro quantitative determination of Protein C antigen

Retrieved on: 
Sunday, July 24, 2022
AG, Protein C, Research, Use, Agglutination, WEST, Company, Diagnosis, Plasma, Vaccine

WEST CHESTER, Ohio, July 24, 2022 /PRNewswire-PRWeb/ -- Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today's highest standards for product quality and cost-efficient delivery.

Key Points: 
  • Aniara Diagnostica is pleased to announce the availability of Liaphen Protein C, an Immuno-turbidimetric method for the in vitro quantitative determination of Protein C antigen in human citrated plasma, using a manual and automated method.
  • LIAPHEN Protein C is an immune-turbidimetric method, based on antigen-antibody reaction: Protein C antigen (PC:Ag) of the sample reacts with latex particles sensitized with rabbit antibodies, leading to latex particles agglutination.
  • The entire Aniara product line is available for purchase at http://www.aniara.com .
  • The Company distributes products in North America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

Global Coagulation Testing Lab and POC Market (2022 to 2026) - Analysis of Current and Emerging Technologies and Their Potential Market Applications - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Health, Medical Devices, Cardiology, ACT, Computer, Factor VII, Factor IX, APTT, Thrombin time, Factor XIII, Coagulation, Heparin-induced thrombocytopenia, Fibrinogen, Protein C, The Queen's Award for Enterprise: Innovation (Technology) (2011), Bleeding time, Factor, Activated protein C resistance, Factor X, Prothrombin time, Factor VIII, Prekallikrein, Factor V, Antithrombin, POC, Protein S, Factor XII, Factor XI, Fine chemical, Plasmin

The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.
  • New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation.
  • Coagulation testing will also become more standardized, offering opportunities for quality control products and services.

Mednition Introduces Machine Learning Powered Early Sepsis Detection Model that Doubles 1hr Sepsis Bundle Compliance

Retrieved on: 
Tuesday, September 1, 2020
Software, Other Health, General Health, Data management, Technology, Infectious diseases, Hospitals, Science, Biotechnology, Nursing, Practice Management, Health, Other Science, Medical specialties, Medicine, Branches of biology, Emergency management, First aid, Intensive care medicine, Triage, Machine learning, Protein C

As part of Mednitions flagship machine learning powered solution, KATE , the new model is designed specifically to improve sepsis identification using only information gathered during the ED triage process (no labs).

Key Points: 
  • As part of Mednitions flagship machine learning powered solution, KATE , the new model is designed specifically to improve sepsis identification using only information gathered during the ED triage process (no labs).
  • These results demonstrate our commitment and capability to advancing clinical accuracy with machine learning, said Christian Reilly, co-founder of Mednition.
  • The enhancement of KATE for early sepsis detection used the same clinical data science methodology as the KATE triage service.
  • For more information about the Mednition early sepsis detection solution and to get an online demonstration of its capabilities, contact [email protected] or VISIT MEDNITION ONLINE AT EN20X, Sept. 9 11.

Beckman Coulter's New Procalcitonin Assay Helps Physicians Accurately Identify Patients at Risk for Progression to Septic Shock

Retrieved on: 
Tuesday, March 26, 2019
Medical specialties, Medicine, Intensive care medicine, Medical emergencies, Sepsis, Septic shock, Coulter, Septic, Beckman, Protein C

The state-of-the-art sensitivity and low-end precision of Access PCT assay combined with short incubation time, helps physicians assess the risk of patients progressing to severe sepsis or septic shock, helps physicians in the risk assessment of critically ill patients in danger of progression to severe sepsis or septic shock, with test results available in under 20 minutes.

Key Points: 
  • The state-of-the-art sensitivity and low-end precision of Access PCT assay combined with short incubation time, helps physicians assess the risk of patients progressing to severe sepsis or septic shock, helps physicians in the risk assessment of critically ill patients in danger of progression to severe sepsis or septic shock, with test results available in under 20 minutes.
  • The ability to rapidly diagnose suspected sepsis patients and determine appropriate care and treatment is critical, as earlier administration of antibiotics is highly correlated with increased patient survival."
  • Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.